Registry of biomedical companies:
[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 449 active entries
2420 NE 61st Ave
PORTLAND, 97213
United States of America, Oregon
Phone: 503 295 2775 Fax: 503 295 2757 Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Description:
Founded by a world-renowned, award-winning academic research scientist in 1997, Dimera has been acknowledged by NIH by multiple Phase II Small Business Innovative Research (SBIR) grants and other federal grant funding. Dimera discoveries have created a new drug platform for unmet cardiovascular (CV) needs, especially for angina pectoris (AP) symptoms of heart disease in women. Dimera patents address treatment, prevention, and diagnostics based on suppression of a key target gene in the coronary artery wall. The result is major reduction in the incidence of AP, even in women for whom even combinations of other drugs are unsatisfactory. Previously unrecognized functional (blood vessel reactivity)-- in addition to known structural (plaques and clots) malady discoveries--are a significant breakthrough in CV medicine. With these major discoveries, Dimera plans to license this inventive treatment modality using DP9 transdermal progesterone cream and patches to treat angina pectoris. Dimera correctly predicted (5 years before the outcome of the Women's Health Initiative) that progesterone, the endogenous human hormone, plays an important role in reducing risk in menopausal women. DP9 was developed to address this need, and has advanced through the rigorous FDA approval process. Dimera has achieved proof-of-concept, now independently confirmed, and secured highly consistent pilot phase III human randomized clinical trial data. Dimera holds 4 patents covering CV uses of progesterone. Dimera has FDA approval and all requisites for defined marketing trials with 1) Special Protocol Assessment (SPA), 2) Chemical Manufacturing Controls (CMC), and 3) clinical investigators selected who have identified and screened highly motivated women for top quality andomized, controlled trials. These Phase III clinical trials for treatment of AP may begin as early as the next quarter after securing capital; the 6-month trials are the last step needed to secure FDA New Drug Application (NDA) marketing approval, allowing DP9 launch. The anticipated patient pool for an FDA-approved prescription drug to treat angina pectoris as a symptom of heart disease now exceeds 3.2 million U.S. women, a >$1 billion annual market in the U.S. alone. Dimera has discovered and developed this gene expression strategy successfully solving unmet needs important in CV dysfunction. By addressing the CV co-morbidity of aging at the gene level--rather than merely addressing purely symptomatic relief--Dimera provides a truly innovative drug development platform built upon multiple rapidly emerging, exciting insights into the cell and molecular biology of the blood vessel wall.
Selected Categories:
Last update of this entry: August 30, 2022
|